Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ERAS-4001 · 1 trial · 1 indication
Based on toxicities observed
Based on toxicities observed
Based on toxicities observed
Incidence and severity of treatment-emergent AEs and serious AEs
Maximum plasma concentration of ERAS-4001
Time of achieve maximum plasma concentration of ERAS-4001
Area under the plasma concentration-time curve of ERAS-4001
Half-life of ERAS-4001
| Arm | Type | Description |
|---|---|---|
| ERAS-4001 Monotherapy Dose Optimization. | EXPERIMENTAL | Escalating doses of ERAS-4001 administered orally. |
| ERAS-4001 Combination Dose Optimization | EXPERIMENTAL | ERAS-4001 administered orally with another investigational agent. |
| Name | Type | Description |
|---|---|---|
| ERAS-4001 | DRUG | ERAS-4001 Administered orally |
| ERAS-4001 in combination | DRUG | ERAS-4001 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration. |
Inclusion Criteria: * Age ≥ 18 years * Willing and able to give written informed consent * Pathological documentation of tumor type and mutation prior to the first dose of study drug(s) * There is no available standard systemic therapy available for the patient's tumor histology and/or molecular bi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ERAS-4001 is an investigational small molecule being developed for the treatment of metastatic solid tumors. It is currently in Phase 1 clinical development and is not yet approved by the FDA. The drug is being studied in patients with advanced or metastatic solid tumors.
ERAS-4001 targets KRAS, a gene that encodes a protein involved in cell signaling and growth. By targeting KRAS, the drug aims to interfere with pathways that drive tumor growth. This mechanism is being evaluated in the context of metastatic solid tumors.
ERAS-4001 is being developed by Erasca, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol ERAS. Erasca is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
ERAS-4001 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial is currently recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy in patients with metastatic solid tumors.
ERAS-4001 is being studied in a Phase 1 clinical trial with the identifier NCT07021898. This trial is titled 'A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors' and is currently recruiting participants in the United States. The trial aims to enroll approximately 200 patients aged 18 years and older.
ERAS-4001 is a distinct investigational drug developed by Erasca, Inc. While it targets KRAS, it is not the same as other KRAS inhibitors. The drug is currently in Phase 1 trials for metastatic solid tumors, and its specific properties and efficacy are being evaluated separately from other agents in this class.